HOME
SEARCH
RSS FEED
SUBSCRIBE
Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination
Case ID:
TAB-2642
Web Published:
12/6/2022
Description:
CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Recombinant_Pan-Lyssavirus_for_Use_i n_Rabies_and_Broad-Lyssavirus_Vaccination
Category(s):
Licensing
Infectious Disease
Therapeutics
Vaccines
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
LPM
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov
Inventors:
Charles Rupprecht
Ivan Kuzmin
Xianfu Wu
Keywords:
Against
CDC Docket Import
CDC Docket Import CDC Prosecuting
DB4XXX
DBXXXX
DC1XXX
DC5BXX
DC5XXX
DCXXXX
DXXXXX
PAN-LYSSAVIRUS
rabies
vaccines
Home
|
Search
|
RSS
|
Subscribe
© 2025. All Rights Reserved. Powered by
Inteum